Navigation Links
Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
Date:1/17/2013

Geneva, Switzerland (PRWEB) January 16, 2013

Selexis SA announced today data from the Company’s SUREtechnology Platform™ will be presented at the 12th Annual PepTalk Conference, January 21-25, 2013 at the Renaissance Hotel & Palm Springs Convention Center in Palm Springs, California.

Selexis’ CEO, Igor Fisch, Ph.D., will present, “SURE CHO-M plus – Selexis’ Next Generation Cell Lines for Overcoming Expression Bottlenecks,” on Thursday, January 24 at 9:50 AM as part of the Pipeline 4: Expression - ‘Fine-Tuning Expression in CHO’ tract.

Presentation Abstract
With certain proteins, optimal productivity cannot be achieved solely by elevated transcription. The secretory pathway needs to be modified to adjust for the increased load. The Selexis SURE CHO-M plus™ panel of modified cell lines addresses different secretory bottlenecks and provides a powerful tool for optimizing expression of difficult-to-express proteins.

Additionally, Zymeworks’ Director of External R&D and Alliances, David Poon, Ph.D., will present, “Bispecific Antibodies From a Novel Stable Expression Platform – Case Study: Development of an Azymetric™ Antibody Using the Selexis SUREtechnology Platform™,” on Friday, January 25 at 9:50 AM as part of the Pipeline 3: Biotherapeutics - ‘Bispecific Antibody Therapeutics’ tract.

Presentation Abstract
The Zymeworks Azymetric™ platform is an IgG1-based bispecific antibody formed by assembly of engineered heterodimeric heavy chains. Stable, high-expressing CHO clones of an Azymetric™ antibody were isolated in 7 weeks using Selexis SUREtechnology™. The bispecific antibody product was > 97% pure heterodimer as assessed by MS.

Dr. Fisch and the company’s VP of business development, Dr. Yemi Onakunle, will be available for questions at Selexis booth 201 from January 21 - 25. Please see conference website for complete schedule.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information, visit http://www.selexis.com

About Zymeworks Inc.
Zymeworks is a privately held biotechnology company that is developing best-in-class antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. Zymeworks is focused on growing its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.
For more information, visit http://www.zymeworks.com

Read the full story at http://www.prweb.com/releases/peptalk_selexis_proteins/bispesific_antibodies/prweb10329768.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
2. Selexis SA to Present at Biotech Showcase 2012
3. 1DegreeBio Expands its Product Review Platform Across Life Sciences
4. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
5. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
6. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
7. Automated Online Sample Preparation Comes to Waters UltraPerformance Liquid Chromatography (UPLC) Platform
8. New Crowdfunding Platform, ScitechStarter, Focuses on Science and Technology Innovators
9. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
10. New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
11. New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its ... new website makes it easy to navigate through the site whether you’re in ... detailed product information, educational industry content and visit the company’s social media accounts, ...
(Date:8/11/2017)... ... , ... A staple in the community for more than 60 years, Bill ... including a new digital marketing strategy and updated logo. , As part of the ... with the South Texas Blood & Tissue Center for the month of August. ...
(Date:8/10/2017)... ... August 09, 2017 , ... ... applications in the clinic is here. The team at Capricor Therapeutics, Inc. utilized ... medium for clinical studies. , Dr. Travis Antes, head of analytical development ...
(Date:8/10/2017)... , ... August 10, 2017 , ... ... agreement establishing Kinokuniya Company Ltd. as its exclusive sales representative for SPIE Journals ... representative for the SPIE Digital Library in Japan. , “We look forward to ...
Breaking Biology Technology:
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):